Project: Streamlined Streptomyces cell factories for industrial production of valuable natural products
| Acronym | MISSION (Reference Number: 100) |
| Duration | 01/05/2018 - 30/04/2021 |
| Project Topic | Natural products cover a unique chemical space, which is particularly well-suited for the development of antibiotics and anticancer drugs. Actinomycetes are the richest source of natural products such as antibiotics for medical, veterinary and agricultural use, and therefore represent a class of bacteria of considerable interest for the human welfare. Indeed, there are huge number of novel compounds discovered so far, however, the supply of sufficient amounts for studying of pharmacological properties is a significant bottleneck in drug development. Our project will create a robust natural products supply platform based on the powerful industrial oxytetracycline overproducer Streptomyces rimosus. The concept integrates systems and synthetic biology with bioinformatics and process engineering into a purpose-driven and engineering workflow. Multi-omics analysis of this strain will deliver key insights for targeted optimization into superior chassis. During development, the iterative and interactive combination of carefully tailored experimental and computer-modelling approaches will support the prediction of multi-combinatorial genetic traits to develop a superior microbial chassis. A full range of new synthetic parts, such as fine-tuned promoters, terminators and regulatory circuits as well as cutting-edge CRISPR/Cas9 genetic engineering will be developed for an exact, marker-less and fast translation of identified, desired features into a clear genetic language, operated by the created S. rimosus cells. In addition to biosynthetic power, project will consider cellular genetic stability, process tolerance and robustness by pre-early integration of expected needs from industrial partners into the design process. The project will enable a tailor-optimised production of valuable bioactive compounds for downstream development as pharmaceuticals. |
|
Project Results (after finalisation) |
|
| Network | ERA CoBioTech |
| Call | ERA CoBioTech “Biotechnology for a sustainable bioeconomy” |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | University of Saarland | Coordinator | Germany |
| 2 | Helmholtz- Zentrum für Infektionsforschung | Partner | Germany |
| 3 | University of Ljubljana | Partner | Slovenia |
| 4 | ENTRECHEM | Partner | Spain |
| 5 | Novartis (Lek pharmaceuticals d.d.) | Partner | Slovenia |